France Grants Compassionate Access to Gene Therapy LUMEVOQ®
December 22, 2025 | Paris, France — GenSight Biologics announced that France’s medicines safety authority has granted Compassionate Use...
rare diseases
Advertisement
Sharp Therapeutics Strengthens Path to Gaucher Trials
December 19, 2025 | Pittsburgh, Pennsylvania and Toronto, Ontario — Sharp Therapeutics Corp. has announced an updated non-brokered private...
DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
KalVista Pharmaceuticals Highlights EKTERLY®’s Promise for Children and Strong Patient Satisfaction in HAE Treatment
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
Gefurulimab Shows Early and Sustained Efficacy in gMG Patients
Cambridge, UK, 30 October 2025 – Alexion, AstraZeneca Rare Disease, today announced positive results from the global Phase III...
Advertisements
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
Novartis Expands RNA Therapeutics Portfolio with Avidity Acquisition
Basel, Switzerland – October 26, 2025: Novartis AG announced its agreement to acquire Avidity Biosciences, a U.S. biotechnology company...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Kedrion Biopharma Launches YIMMUGO® for PI in the U.S.
FORT LEE, N.J., October 9, 2025 — Kedrion Biopharma today announced the U.S. commercial launch of YIMMUGO® (Immune Globulin...
FDA Grants RMAT Designation to Avobis Bio’s AVB-114 for Crohn’s Perianal Fistulas
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
Advertisement
